Tirzepatide
FDA APPROVEDDual GIP/GLP-1 receptor agonist | Weight loss & diabetes
Overview
What is Tirzepatide?
Tirzepatide is a dual agonist of the GIP and GLP-1 receptors, approved by the FDA for both type 2 diabetes and chronic weight management (Mounjaro, Zepbound). It has shown outstanding results compared with single-receptor agonists.
Key benefits
Notable weight loss (15-22% of body weight), better diabetes control, lower cardiovascular risk, greater insulin sensitivity, appetite suppression and preservation of muscle mass.
Mechanism of action
Dual agonist of the GIP and GLP-1 receptors: glucose-dependent insulin stimulation, delayed gastric emptying, glucagon suppression and central satiety signaling through hypothalamic pathways.
Quick start guide
What to expect
- Appetite reduction within the first 1-3 days after injection.
- Mild to moderate nausea during the first 2-4 weeks (usually improves noticeably).
- Loss of 0.5-1.5 kg per week during the active weight-loss phase.
- Better blood sugar control within 1-2 weeks in people with diabetes.
- Noticeable reduction in cravings and greater satisfaction with smaller portions.
- Greater satiety and meal satisfaction for 6-7 days per injection.
- Possible fatigue during the first weeks of adaptation.
- Peak weight-loss effects usually between weeks 16-24.
- Improved energy levels after the initial adaptation period.
Side effects & safety
- Start with the lowest dose (2.5 mg) and increase gradually every 4 weeks to minimize side effects.
- Contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.
- Watch for signs of acute pancreatitis (severe, persistent abdominal pain radiating to the back).
- Significant nausea is common at first but usually improves — stay hydrated and eat smaller meals.
- Requires a prescription and medical supervision — not available over the counter.
- Store in the fridge between 2-8 °C, never freeze or shake vigorously.
- May require adjusting other diabetes medications to avoid hypoglycemia.
- Severe allergic reaction: rash, itching, swelling of the face, lips or throat, or difficulty breathing.
- Severe, persistent abdominal pain radiating to the back (possible pancreatitis).
- Persistent vomiting or diarrhea with signs of dehydration.
- Lump or swelling in the neck, hoarseness or difficulty swallowing.
- Pain in the upper right abdomen or yellowing of the skin (possible gallbladder problem).
- Symptoms of severe hypoglycemia: confusion, sweating, tremors or fainting.
- Vision changes or worsening of diabetic retinopathy.
- Racing heartbeat or persistent palpitations.
- If you are pregnant or plan to be soon.
Frequently asked questions
What is Tirzepatide?
Tirzepatide is a dual agonist of the GIP and GLP-1 receptors, approved by the FDA for type 2 diabetes and weight management (Mounjaro, Zepbound).
What is Tirzepatide used for?
It is used for weight loss and glucose control, with outstanding results compared with single-receptor agonists.
How does Tirzepatide work?
It activates the GIP and GLP-1 receptors at the same time: it stimulates glucose-dependent insulin, slows gastric emptying and reduces appetite.
How long does Tirzepatide take to work?
Appetite reduction appears in the first days or weeks; weight loss is progressive and peak effects are seen after months.
What is the usual Tirzepatide dose?
It starts at 2.5 mg weekly and is increased every 4 weeks up to the target dose (up to 15 mg). The schedule is decided by a professional.
How is Tirzepatide administered?
By subcutaneous injection once a week in the abdomen, thigh or arm.
How much weight can you lose with Tirzepatide?
In clinical trials, average reductions of 15-22% of body weight were observed, depending on the dose and the person.
How is Tirzepatide stored?
Refrigerated between 2 and 8 °C. More information in the storage guide.
What are the side effects of Tirzepatide?
Mainly digestive: nausea, diarrhea, vomiting and constipation, especially when increasing the dose.
What is the difference between Tirzepatide and Semaglutide?
Tirzepatide acts on two receptors (GIP and GLP-1) and semaglutide on one (GLP-1); the former usually shows greater average weight loss.
Is Tirzepatide approved?
Yes, it is approved by the FDA for type 2 diabetes and weight management.
Who should not use Tirzepatide?
Contraindicated with a history of medullary thyroid carcinoma or MEN 2, and during pregnancy.
Research areas
- Weight loss
- Type 2 diabetes control
- Appetite reduction
- Metabolic health
- Blood glucose control
Related peptides
- Semaglutide — GLP-1 receptor agonist for weight and diabetes.
- Retatrutide — Triple GLP-1/GIP/glucagon agonist in research.
- Tesamorelin — GHRH analog researched for visceral fat.
Related articles
Related topics
- Tirzepatide for weight loss
- Tirzepatide and diabetes
- Tirzepatide dose
- Tirzepatide side effects
- Tirzepatide vs Semaglutide
- Tirzepatide Mounjaro and Zepbound
Summary
What it is: Dual agonist of the GIP and GLP-1 receptors (Mounjaro, Zepbound).
How it is researched: Weekly subcutaneous injection; 2.5 to 15 mg.
Key features: Reduces appetite and glucose; average 15-22% loss. FDA-approved.
Related peptides: Semaglutide, Retatrutide and Tesamorelin.